DOJ Begins Targeting COVID-19 Fraud Schemes
Client Alert | 1 min read | 03.20.20
In response to increased reporting of COVID-19-related fraud and misconduct, on March 16, 2020 Attorney General Barr directed all U.S. Attorneys to prioritize the prosecution of wrongdoers seeking to profit from this national crisis. Barr stated in his directive that "[t]he pandemic is dangerous enough without wrongdoers seeking to profit from public panic and this sort of conduct cannot be tolerated." Examples of such conduct include the sale of fake cures for COVID-19, phishing emails posing as the World Health Organization or the Centers for Disease Control and Prevention, and malware being inserted into mobile apps designed to track the spread of the virus.
U.S. Attorneys have already started responding to the directive. The U.S. Attorneys in the Western District of Pennsylvania and the Southern District of Mississippi have each appointed a dedicated COVID-19 fraud coordinator, while other U.S. Attorneys have launched hotlines and educational campaigns to combat COVID-19-related fraud. They are joined by other U.S. agencies that are starting to ring similar alarm bells, like the GSA which put out a notice this week that it has received reports of companies fraudulently claiming to be GSA vendors to mislead consumers into paying exorbitant prices for products associated with COVID-19. Over the coming days and weeks, we expect that U.S. Attorneys and agencies across the country will further shift their criminal and civil enforcement priorities to cases stemming from the COVID-19 crisis.
Contacts
Insights
Client Alert | 2 min read | 11.14.25
Claim construction is a key stage of most patent litigations, where the court must decide the meaning of any disputed terms in the patent claims. Generally, claim terms are given their plain and ordinary meaning except under two circumstances: (1) when the patentee acts as its own lexicographer and sets out a definition for the term; and (2) when the patentee disavows the full scope of the term either in the specification or during prosecution. Thorner v. Sony Comput. Ent. Am. LLC, 669 F.3d 1362, 1365 (Fed. Cir. 2012). The Federal Circuit’s recent decision in Aortic Innovations LLC v. Edwards Lifesciences Corp. highlights that patentees can act as their own lexicographers through consistent, interchangeable usage of terms across the specification, effectively defining terms by implication.
Client Alert | 6 min read | 11.14.25
Microplastics Update: Regulatory and Litigation Developments in 2025
Client Alert | 6 min read | 11.13.25

